AstraZeneca (AZN) said Tuesday a phase 3 trial of Ultomiris in adults with Immunoglobulin A nephropathy, a rare kidney disease, met its primary endpoint.
The study showed a statistically significant reduction in proteinuria, based on 24-hour urine protein creatinine ratio at week 34, the company said.
AstraZeneca said it plans to submit the data to regulatory authorities while continuing the trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments